ethyl 4-(2-(dicyanomethylene)hydrazinyl)benzoate | 3720-46-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-(2-(dicyanomethylene)hydrazinyl)benzoate
• 英文别名: 4-(N'-dicyanomethylene-hydrazino)benzoic acid ethyl ester；4-(N'-dicyanomethylenehydrazino)benzoic acid ethyl ester；ethyl 4-[2-(dicyanomethylidene)hydrazinyl]benzoate
• CAS: 3720-46-5
• 化学式: C₁₂H₁₀N₄O₂
• 分子量: 242.237
• InChiKey: FSJDMZWOBVIXBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  98.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-(2-(dicyanomethylene)hydrazinyl)benzoate 在 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 硝基甲烷 为溶剂， 反应 3.0h， 生成 4-amino-2,6-dioxo-5-(p-ethoxycarbonyl-phenylhydrazono)-1,2,5,6-tetrahydropyrid-3-yl-pyridiniumchlorid
  参考文献：
  名称：

  Synthese und Reaktionen von 2-Arylhydrazono-2-cyan-N,N-dialkyl-acetamidinen

  摘要：

  The title compounds 3 were synthesized by reaction of arlyhydrazono-malononitriles 1 with secondary amines and used for subsequent cyclization reactions. Thus, 3 undergoes cyclooxidation by treatment with CuSO4/pyridine to form the 5-dialkylamino-2-aryl-1,2,3-triazolo-4-carbonitriles 4. From 4 a and hydrazine hydrate/DMF the 4-(1,3,4-triazolyl-5)-1,2,3-triazole 5 c is obtainable. The chloroacetylation of 3 is accompanied by hydrolysis of the amino group to yield the arylhydrazono-N-chloracetyl cyanoacetamides 6. The quaternisation of 6 with pyridins is followed by the Thorpe cyclization to form the 4-amino-5-arylazo-6-hydroxy-3-pyridinio-pyrid-2-on-chlorides 8, useful as cationic dyes. The reaction of 3 with trichloroacetonitriles yields the 5-arylazo-4-imino-2-trichlormethyl-1,4-dihydropyrimidines 10 a-c which can be converted into the 5-arylazo-2-hydrazino-pyrimidine derivatives 10 d-f.From 10 d the 6-phenylazo-triazolo[4,3-a]pyrimidine derivative 11 is obtainable. From 3 and phenylisothiocyanate the 5-arylazo-4-imino-1,4-dihydropyrimidin-2-thiones 12 arise. The structures were investigated by C-13-NMR-spectroscopy.

  DOI：

  10.1007/bf00809365
• 作为产物：
  描述：

  苯佐卡因 、 丙二腈 在 亚硝酸特丁酯 作用下， 以 乙腈 为溶剂， 以95%的产率得到ethyl 4-(2-(dicyanomethylene)hydrazinyl)benzoate
  参考文献：
  名称：

  5-氨基-2-芳基-2H- [1,2,3]-三唑-4-腈的多步流合成

  摘要：

  1,2,3-三唑已成为当代药物化学中最重要的杂环之一。铜催化的惠斯根环加成反应的发展已使1取代的1,2,3-三唑的有效合成成为可能。但是，仅有几种方法可用于选择性制备2-取代的1,2,3-三唑异构体。在这种情况下，我们决定开发一种高效的流动合成方法，以制备各种2-芳基-1,2,3-三唑。我们的策略涉及在连续流动条件下的三步合成，该过程从苯胺的重氮化开始，然后与丙二腈反应，然后亲核加成胺，最后采用催化铜（II）环化。在线猝灭已经解决了与反应性重氮物质形成相关的潜在安全隐患。使用流动设备可以通过可靠地控制反应条件实现可靠的按比例放大过程。2-取代的1,2,3-三唑的合成具有良好的收率和优异的选择性，因此提供了1,2,3-三唑的广泛选择。

  DOI：

  10.1002/chem.201402074

文献信息

• Pyrazole compounds
  申请人：——

  公开号：US20030060453A1

  公开（公告）日：2003-03-27

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  提供药物组合物和化合物。发明的化合物显示出抗增殖活性，并且可能促进缺乏正常细胞周期和死亡调控的细胞的凋亡。发明的一个实施例提供了化合物与生理可接受载体组合的药物组合物。该药物组合物可用于治疗过度增殖障碍，包括肿瘤生长、淋巴增殖性疾病、血管生成。发明的化合物是取代吡唑和吡唑啉。
• Synthesis of 2-arylamino-3-cyanoquinolines <i>via</i> a cascade reaction through a nitrilium intermediate
  作者：Mani Ramanathan、Jing Wan、Yi-Hung Liu、Shie-Ming Peng、Shiuh-Tzung Liu

  DOI：10.1039/c9ob02427a

  日期：——

  method for the preparation of 2-amino-3-cyanoquinolines from readily available aryldiazonium salts, 2-aminoarylketones, and malononitrile via a cascade reaction is reported. This one-pot approach involves the in situ generation of an N-arylnitrilium intermediate from the direct reaction of aryldiazonium salts and malononitrile, which undergoes intermolecular amination, Knoevenagel condensation, and then

  报道了一种通过级联反应从易得的芳基重氮盐，2-氨基芳基酮和丙二腈制备2-氨基-3-氰基喹啉的新方法。这种一锅法涉及从芳基重氮盐和丙二腈的直接反应中原位生成N-芳基腈中间体，该中间体进行分子间胺化，Knoevenagel缩合，然后进行芳构化以中度到良好的收率得到所需化合物。该方法具有快速组装C2和C3功能化喹啉的特点。
• Immugenic compositions and diagnostic and therapeutic uses thereof
  申请人：Zhang Zaihui

  公开号：US20050272709A1

  公开（公告）日：2005-12-08

  Pharmaceutical compositions and compounds are provided. The compounds of the invention deomonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  本发明提供了制药组合物和化合物。本发明的化合物表现出抗增殖活性，并可能促进缺乏正常细胞周期和死亡调节的细胞凋亡。在本发明的一种实施例中，提供了化合物与生理可接受载体的制药组合物。这些制药组合物可用于治疗高增殖性疾病，包括肿瘤生长、淋巴增殖性疾病、血管生成等疾病。本发明的化合物是取代的吡唑和吡唑啉。
• Hydrazonopyrazole derivatives and their use as therapeutics
  申请人：Valocor Therapeutics, Inc.

  公开号：US07875728B2

  公开（公告）日：2011-01-25

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  本发明提供了药物组合物和化合物。本发明的化合物表现出抗增殖活性，并可能促进缺乏正常细胞周期和死亡调节的细胞凋亡。在本发明的一种实施例中，提供了化合物与生理上可接受的载体组合的药物组合物。这些药物组合物在治疗增生性疾病方面是有用的，这些疾病包括肿瘤生长，淋巴增生性疾病和血管生成。本发明的化合物是取代的吡唑和吡唑烷。
• HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS
  申请人：Zhang Zaihui

  公开号：US20110237783A1

  公开（公告）日：2011-09-29

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  本发明提供了药物组合物和化合物。本发明的化合物表现出抗增殖活性，并可能促进缺乏正常细胞周期和死亡调节的细胞凋亡。在本发明的一个实施例中，提供了与生理学上可接受的载体结合的化合物的药物组合物。这些药物组合物在治疗增生性疾病方面有用，这些疾病包括肿瘤生长、淋巴增生性疾病和血管生成等疾病。本发明的化合物是取代的吡唑和吡唑啉。